Page 171 - Phytochemistry 2 (06-PG 605)
P. 171
Mechanism of action:
Omacetaxine prevents peptide elongation by binding the Asite
in the large ribosomal subunit, thus blocking correct
positioning of the amino-acid side chains of tRNAs.
Omacetaxine received FDA approval in 2012 for the treatment
of Chronic myeloid leukemia (CML) patients whohave failed
two or more tyrosine kinase inhibitors (TKI) treatments
(specific, targeted therapy).
HHT is a potent anticancer agent, efficacious in several
aggressive blood malignancies
